What did @brandynitti actually say?
In a 181K-view TikTok, @brandynitti walked through five estrogen delivery methods for trans women: oral pills, sublingual absorption, gels/creams/patches, injectables, and pellet implants. She takes oral estradiol and spironolactone herself, called oral the "most common way HRT is administered," flagged a "slightly higher risk for blood clots" with oral estrogen, and noted that sublingual dosing "absorbs directly into the bloodstream bypassing the liver" with potentially lower clotting risk. She admitted limited knowledge about gels and implants and described injectables as causing hormonal "highs and lows." She closed by recommending viewers consult an endocrinologist.
Overall, this is a personal experience video with some clinical accuracy woven in, but several claims deserve a closer look before 181K people treat them as medical fact.
Does the science back this up?
Mostly, yes, on the big-picture stuff. The liver metabolism concern with oral estradiol is real and well-documented, and the sublingual advantage she describes has genuine pharmacokinetic support. But the specifics are messier than she lets on.
Oral estradiol does increase first-pass hepatic metabolism, which raises sex hormone-binding globulin and clotting factors like factor VII and fibrinogen. A 2021 analysis by Vinogradova et al. in BMJ found oral estradiol carried meaningfully higher venous thromboembolism risk than transdermal routes in cisgender women. Sublingual estradiol bypasses most of that first-pass effect, producing higher estradiol-to-estrone ratios, a point confirmed by Kuhl (2005) in Climacteric. So her core logic on oral versus sublingual holds up.
The injectable "highs and lows" claim is pharmacologically accurate. Estradiol valerate and cypionate have half-lives that create peak-and-trough cycles, particularly with less frequent injection schedules. This is not unique to her experience. It is a documented pharmacokinetic reality (Rosenfield & Cooke, 2021, JCEM).
What did they get right (or wrong)?
She got the liver-bypass mechanism right for sublingual dosing, and the injectable hormone fluctuation complaint is textbook pharmacokinetics. Credit where it is due.
What she got wrong: calling oral HRT "the most common way" is debatable and varies by country and provider. In the U.S., patches and gels have significant clinical use, and the Endocrine Society guidelines do not rank oral as the default preferred route. Dismissing gels and patches as "a lot of work" without any clinical context does her audience a disservice. Transdermal estradiol carries the lowest thrombosis risk of all methods, a fact that matters enormously for patients with clotting risk factors, obesity, or migraines with aura.
Her implant summary, "hard to adjust dosage wise," is accurate but incomplete. Pellet dosing unpredictability is a known clinical concern, but implants are rarely used in feminizing HRT in the U.S., so the framing makes them sound more common than they are.
What should you actually know?
Route of administration is a clinical decision, not a lifestyle preference, even though personal comfort matters. Here is what the evidence actually supports.
- Transdermal estradiol (patches, gels) has the lowest venous thromboembolism risk of any route. If a patient has clotting risk factors, this is the first conversation to have with a provider, not a method to brush off as inconvenient.
- Sublingual estradiol produces more variable serum levels than transdermal routes, though better than oral in terms of liver impact. It is not formally FDA-approved as a sublingual formulation, meaning patients are using oral tablets off-label sublingually.
- Spironolactone, which @brandynitti mentions taking, is an anti-androgen commonly used in U.S. feminizing HRT protocols, but it is not universally used globally. Bicalutamide and GnRH analogues are alternatives with different risk profiles.
- Injectable estradiol does cause peak-and-trough fluctuations, but more frequent injections (weekly versus biweekly) can flatten that curve significantly. It is a management problem, not an inherent disqualifier.
- The Endocrine Society's 2017 clinical practice guidelines recommend individualized route selection based on patient history, not a one-size preference. Endocrinologist consultation, as @brandynitti recommends at the end, is genuinely the right call.
Should you take medical cues from this video?
For general awareness of what options exist, this video is a reasonable starting point. For deciding your own HRT route, it is not enough. @brandynitti is transparent that her opinions are personal, and she correctly tells viewers to see an endocrinologist. That caveat matters. Her dismissal of transdermal methods as inconvenient could lead viewers with real clotting risk to skip the safest available option. That gap between personal preference and clinical risk stratification is exactly where a provider conversation becomes non-negotiable.